2025/02/05 更新

写真a

オマタ　ジヨウ
尾股　丈
OMATA Jiyo
所属
医歯学総合病院 耳鼻咽喉・頭頸部外科 助教
職名
助教
外部リンク

学位

  • 学士 （ 2010年3月   新潟大学 ）

経歴

  • 新潟大学   医歯学総合病院 耳鼻咽喉・頭頸部外科   助教

    2023年6月 - 現在

 

論文

  • Safety and efficacy of neoadjuvant chemotherapy with paclitaxel, carboplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma

    Ryoko Tanaka, Yushi Ueki, Shusuke Ohshima, Jo Omata, Yusuke Yokoyama, Takeshi Takahashi, Ryusuke Shodo, Keisuke Yamazaki, Kohei Ohtaki, Takafumi Togashi, Arata Horii

    International Journal of Clinical Oncology   2024年

    　詳細を見る

    掲載種別：研究論文（学術雑誌）  

    Background: As a substantial waiting time is usually required for radical surgery, safe and effective preoperative neoadjuvant chemotherapy (NAC) is desired for the treatment of locally advanced head and neck squamous cell carcinoma (HNSCC). However, the significance of NAC in advanced HNSCC is still unclear. This study aimed to assess the safety and efficacy of NAC using the paclitaxel, carboplatin, and cetuximab (PCE) regimen. Methods: We retrospectively evaluated the background characteristics, incidence of adverse events, overall response rate (ORR), pathological response, recurrence-free survival (RFS), and overall survival (OS) in 26 patients. Patients receiving the PCE regimen were further divided into two groups based on the number of chemotherapy cycles (one cycle or more) and eligibility for cisplatin. Patients aged ≥ 75 years and those with an estimated glomerular filtration rate (eGFR) < 60 mL/min were classified as ineligible for cisplatin. Results: The median age was 70 (27–81) years. The median eGFR at treatment initiation was 63.2 (41.1–89.7) mL/min. Fourteen (53.8%) patients were ineligible for cisplatin. Grade 3 or higher neutropenia was observed in 11 of 25 (42.3%) patients. No delay in or withdrawal from surgery was observed. The ORR was 65.4%. The 2-year RFS and OS were 61.5% and 76.7%, respectively. No significant differences in safety and efficacy between the number of chemotherapy cycles and cisplatin eligibility were observed. Conclusion: NAC using the PCE regimen for patients with locally advanced HNSCC, including cisplatin-ineligible patients, has acceptable toxicity and favorable efficacy.

    DOI： 10.1007/s10147-024-02545-9

    Scopus

    researchmap

  • Role of eosinophilia in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab: Prediction of immune-related adverse events and favorable outcome. 国際誌

    Yushi Ueki, Shusuke Ohshima, Jo Omata, Yusuke Yokoyama, Takeshi Takahashi, Ryusuke Shodo, Keisuke Yamazaki, Arata Horii

    Cancer medicine   12 ( 22 )   20810 - 20820   2023年11月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    INTRODUCTION: Immune-related adverse events (irAEs) are prognostic factors for patients on nivolumab. However, predictors of irAEs have not yet been identified. We aimed to investigate the predictors of irAEs occurrence and nivolumab discontinuation due to irAEs. METHODS: Sixty-two patients with recurrent/metastatic head and neck squamous cell carcinoma received nivolumab therapy between June 2017 and December 2020. Treatment outcome was compared between the groups with or without irAEs. The irAE (+) group was further divided by nivolumab discontinuation. Progression-free survival (PFS) and overall survival (OS) were compared between the groups. Predictors of irAE occurrence were analyzed. RESULTS: Twenty-one patients (33.9%) developed irAEs, and six (28.6%) discontinued nivolumab due to severe irAEs. The irAE (+) group had significantly longer PFS and OS than the irAE (-) group (median PFS, 12.7 vs. 1.9 months; median OS, 33.1 vs. 12.8 months). The treatment outcomes in the discontinuation group were comparable to those in the non-discontinuation group. The maximum absolute eosinophil count (AEC) during nivolumab therapy was significantly higher in the irAE (+) group than in the irAE (-) group (548.8 vs. 182) and higher in the discontinuation group than in the non-discontinuation group (729.3 vs. 368.6). The receiver operating characteristic curve showed that the maximum AEC had a moderate-to-high accuracy for predicting irAE occurrence (area under the curve [AUC], 0.757) and nivolumab discontinuation (AUC, 0.893). DISCUSSION: Monitoring AEC during nivolumab therapy may be useful in predicting irAE occurrence, nivolumab discontinuation, and disease prognosis.

    DOI： 10.1002/cam4.6648

    PubMed

    researchmap

  • 再発転移頭頸部癌に対するペムブロリズマブの治療成績 併用療法と単剤療法の比較

    植木 雄志, 大島 秀介, 尾股 丈, 横山 侑輔, 高橋 剛史, 正道 隆介, 山崎 恵介, 堀井 新

    頭頸部癌   49 ( 2 )   185 - 185   2023年5月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本頭頸部癌学会  

    researchmap

  • 再発転移頭頸部癌に対するペムブロリズマブの治療成績 併用療法と単剤療法の比較

    植木 雄志, 大島 秀介, 尾股 丈, 横山 侑輔, 高橋 剛史, 正道 隆介, 山崎 恵介, 堀井 新

    頭頸部癌   49 ( 2 )   185 - 185   2023年5月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本頭頸部癌学会  

    researchmap

  • 頭頸部悪性腫瘍新患登録33年の変遷 新潟県における検討

    富樫 孝文, 太田 久幸, 田中 亮子, 西條 幸平, 尾股 丈, 横山 侑輔, 高橋 剛史, 正道 隆介, 植木 雄志, 岡部 隆一, 山崎 恵介, 松山 洋, 本田 耕平, 佐藤 雄一郎, 堀井 新, 新潟県頭頸部悪性腫瘍登録委員会

    日本耳鼻咽喉科頭頸部外科学会会報   126 ( 1 )   38 - 45   2023年1月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本耳鼻咽喉科頭頸部外科学会  

    新潟県では,1986年より新潟県頭頸部悪性腫瘍登録委員会が新規症例の腫瘍登録を開始した.このたび本研究では,頭頸部悪性腫瘍発生の経時変化を見ることを目的とし,1986～2018年までの登録症例において年毎の頭頸部悪性腫瘍総数,原発部位別数,粗罹患率を分析し,さらにT分類別でT2以上症例に対するT1以下症例の比率(T1以下/T2以上)を指標として検討した.総数は12,443例で,男性8,619例(69.3%),女性3,824例(30.7%)だった.登録初年度と比べ2018年の年次毎症例数は3.7倍(599例/160例)に増加し,年平均増加率は4.2%で,粗罹患率は4.3倍(26.7/6.2)に増加していた.年齢中央値は4歳(64歳→68歳)上昇しており,高齢化が粗罹患率上昇の要因と考えられた.「T1以下/T2以上」は頭頸部悪性腫瘍全部位では,1986～1996年,1997～2007年,2008～2018年の3年代の間で差はなかったが,下咽頭癌では2008～2018年で,ほかの2年代と比較し有意に上昇していた.すなわち,頭頸部悪性腫瘍全体では30年経過しても早期診断に至っていなかったが,内視鏡などが診断に寄与できる下咽頭では早期発見が可能になってきたことが示唆された.この結果から,頭頸部癌の早期発見のためには,癌検診,特に下咽頭を対象とした検診が有用である可能性が示唆された.(著者抄録)

    researchmap

    その他リンク： https://search.jamas.or.jp/default/link?pub_year=2023&ichushi_jid=J07551&link_issn=&doc_id=20230201440008&doc_link_id=%2Fdz0tokei%2F2023%2F012601%2F009%2F0038-0045%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fdz0tokei%2F2023%2F012601%2F009%2F0038-0045%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • Chemoradiotherapy with 3-weekly CDDP 80 mg/m2 for head and neck squamous cell carcinoma: 5-year survival data from a phase 2 study. 国際誌

    Kohei Otaki, Takeshi Takahashi, Ryoko Tanaka, Kohei Saijo, Jo Omata, Yusuke Yokoyama, Ryusuke Shodo, Yushi Ueki, Keisuke Yamazaki, Hisayuki Ota, Takafumi Togashi, Nao Takahashi, Ryuichi Okabe, Hiroshi Matsuyama, Arata Horii

    Frontiers in surgery   9   1035349 - 1035349   2022年

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    OBJECTIVE: The global standard for chemoradiation therapy (CCRT) for head and neck squamous cell carcinoma is cisplatin 100 mg/m2 administered once every three weeks, although cisplatin 80 mg/m2 is also widely used as an alternative treatment to reduce adverse events in Japan. We aimed to assess the long-term survival outcomes and late adverse events associated with CCRT with a 3-weekly cisplatin dose of 80 mg/m2. METHODS: A phase 2 study on CCRT with a 3-weekly cisplatin dose of 80 mg/m2 was performed in 47 patients between April 2015 and December 2016 at four centers in Japan. Survival outcomes and late adverse events at 5 years after this phase 2 trial were investigated. RESULTS: The median follow-up period was 61 months. The 5-year progression-free survival/overall survival of all 47 patients was 66.0%/76.6%, while that of patients with stage III, IV disease (UICC) was 65.6%/71.9%. Seventeen patients (36%) experienced dysphagia as a late adverse event. Univariate and multivariate analyses revealed a significant association between acute mucositis/low body mass index (BMI) during CCRT and late dysphagia. CONCLUSION: The survival outcomes of CCRT with a 3-weekly cisplatin dose of 80 mg/m2 may be comparable to the previously reported dose of 100 mg/m2. Acute mucositis and low BMI at CCRT were risk factors for late dysphagia, indicating the importance of managing these conditions during CCRT to prevent late adverse events. Caution and care for acute mucositis and swallowing training in patients with low BMI may be important for preventing late-stage dysphagia.

    DOI： 10.3389/fsurg.2022.1035349

    PubMed

    researchmap

  • Treatment Outcomes and the Safety of Chemoradiotherapy With High-Dose CDDP for Elderly Patients With Head and Neck Squamous Cell Carcinoma: A Propensity Score Matching Study. 国際誌

    Jo Omata, Yushi Ueki, Takeshi Takahashi, Ryusuke Shodo, Keisuke Yamazaki, Kohei Saijo, Hisayuki Ota, Takafumi Togashi, Yuichiro Sato, Arata Horii

    Frontiers in surgery   8   753049 - 753049   2021年

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Objective: We aimed to compare the outcomes and safety of chemoradiotherapy (CRT) between elderly and non-elderly patients with head and neck squamous cell carcinoma (HNSCC). It is difficult to assess the causal effect of age because of possible differences in general conditions among individuals. Therefore, we adjusted the background factors of elderly and non-elderly patients using propensity score matching (PSM). Methods: A total of 146 patients with HNSCC who received CRT were divided into an elderly (≥70 years, n = 35) and non-elderly group (<70 years, n = 111). Pre-treatment characteristics, including the performance status, Charlson comorbidity index, body mass index, primary site, and TNM stage were adjusted by PSM. We compared the outcomes and safety of CRT with high-dose single-agent cisplatin (CDDP) as well as outcomes following recurrence between the groups, before and after PSM. Results: The total dose of CDDP administered during CRT was significantly lower in the elderly group before PSM. However, it became comparable to the non-elderly group and adverse events did not differ between the groups following PSM, resulting in a comparable CRT completion rate. Overall-, disease specific-, and progression-free survivals of elderly patients were comparable to those of non-elderly patients following PSM. In contrast, elderly patients with recurrence could receive fewer salvage treatments than their non-elderly counterparts, resulting in worse survival. Conclusions: CRT with high-dose CDDP is safe and effective for the treatment of elderly patients with HNSCC. However, salvage treatments can be rarely conducted for elderly patients with a recurrence, considering a deterioration of their general condition.

    DOI： 10.3389/fsurg.2021.753049

    PubMed

    researchmap

  • 耳下腺腫瘍手術症例における術前・術中検査の検討

    尾股 丈, 太田 久幸, 富樫 孝文, 橋本 茂久

    頭頸部外科   26 ( 3 )   367 - 371   2017年2月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(NPO)日本頭頸部外科学会  

    当科で2010年から2014年までの5年間に、耳下腺腫瘍と診断し手術を施行した123例について検討した。内訳は男性75例、女性48例で、年齢は18～82歳(平均年齢54.3歳)、病理組織診断で良性腫瘍105例、悪性腫瘍18例であった。画像検査、穿刺吸引細胞診、術中迅速検査における良悪性の診断精度について比較し、感度/特異度はCTで58.8%/92.4%、MRIで58.8%/94.9%、穿刺吸引細胞診で30.8%/100%、術中迅速病理診断で75.0%/96.6%だった。診断精度は術中迅速病理診断で最も良好だったが偽陰性を4例、偽陽性を3例認めた。それらの症例では術前検査と術中所見を総合的に判断して術式を決定する必要があった。(著者抄録)

    researchmap

    その他リンク： https://search.jamas.or.jp/default/link?pub_year=2017&ichushi_jid=J04210&link_issn=&doc_id=20170310470016&doc_link_id=10.5106%2Fjjshns.26.367&url=https%3A%2F%2Fdoi.org%2F10.5106%2Fjjshns.26.367&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • 頭頸部領域に再発を繰り返した類上皮血管内皮腫の1例

    尾股 丈, 松山 洋, 正道 隆介, 山崎 洋大, 植木 雄志, 山崎 恵介, 山本 裕, 高橋 姿

    頭頸部外科   25 ( 1 )   55 - 60   2015年6月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(NPO)日本頭頸部外科学会  

    頭頸部領域に再発を繰り返した類上皮血管内皮腫の1例を報告する。症例は40歳女性で、過去12年間に頭蓋骨左側、下顎骨左側、左耳下腺、鼻中隔左側の類上皮血管内皮腫に対して複数の医療機関で摘出術を施行され、経過観察目的に当科紹介となった。初診時は頭頸部領域に腫瘍性病変を認めなかったが、経過中に鼻中隔左側に腫瘤が出現した。生検にて類上皮血管内皮腫再発の診断となり、腫瘍切除術を施行した。腫瘍径と病理組織像から低危険度群に分類されたため、追加治療をせず経過観察を行っており、術後18ヵ月再発を認めていない。本症例では頭頸部領域の片側性再発を繰り返しており、今後も慎重な経過観察が必要と思われた。(著者抄録)

    researchmap

    その他リンク： https://search.jamas.or.jp/default/link?pub_year=2015&ichushi_jid=J04210&link_issn=&doc_id=20150721380009&doc_link_id=10.5106%2Fjjshns.25.55&url=https%3A%2F%2Fdoi.org%2F10.5106%2Fjjshns.25.55&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

▶ 全件表示